SVF
Level A· Stronger Clinical EvidenceSystematic Review

Adipose-Derived Stem Cell, Stromal Vascular Fraction, and Regenerative Cell Enrichment in Fat Grafting: A Systematic Review of Safety and Functional Outcomes.

Hakami AH., Akkur MS., Mahasi KA., Younis MK., AlDafas AF., Al Massloom LH.

Systematic Review on Facial Rejuvenation, published in Cureus (2025) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Cureus (2025)
Country
United States
Reported sample size
—
PMID
41555993
DOI
10.7759/cureus.99599

Abstract (original English)

Adipose-derived stem cell (ADSC)-enhanced fat grafting, including enrichment with stromal vascular fraction (SVF) and adipose-derived regenerative cells (ADRCs), has been increasingly used to improve fat graft survival and regenerative outcomes in reconstructive and aesthetic plastic surgery, yet long-term safety, efficacy, and mechanistic understanding remain variably reported. This systematic review aimed to evaluate real-world clinical evidence on the long-term safety, volume retention, and functional outcomes of ADSC-, SVF-, and ADRC-enriched fat grafting across aesthetic and reconstructive indications. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, comprehensive searches of PubMed, Scopus, Web of Science, and the Cochrane Library identified 3158 studies, of which 12 met the inclusion criteria, encompassing randomized controlled trials and prospective non-randomized clinical studies assessing ADSC-, SVF-, or ADRC-assisted fat grafting with reported outcomes related to graft survival, clinical function, aesthetic performance, or safety. Across studies, ADSC and SVF enrichment generally improved volume retention compared with conventional fat grafting, with several randomized trials demonstrating graft survival rates of 60-80% at three to six months, and ADSC-assisted grafts consistently enhanced dermal regeneration

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Systemic / IVFacial Rejuvenation
View on PubMedDOI

Related research